Lonza Reported to Buy US biologics site from Roche for $1.2 Billion

The SWISS contract drug manufacturer Lonza claimed this wednesday on March 2oth that they have accepted an agreement and gave a green signal to acquire the Genentech manufacturing facility in Vacaville in California, from Roche for $1.2 billion in cash.

Lonza is predicted to invest around 500 million Swiss francs, which is $754.8 million in order to enhance the facility and improve the capabilities all to accommodate the next generation of the mammalian biologics therapies, which the company has claimed in a stalemate.

At the moment, the Vacaville facility has around 330,000 litres of bioreactor capacity which makes this one of the biggest biologics manufacturing siles globally if measured by volume.

-The Vacaville site is a highly valuable strategic acquisition that will make capacity immediately available for our customers and unlock future growth for our biologics division." is what was claimed by Jean-Christophe Hyvert, who is the president of Biologics al Lonza. Read more- https://luminarytimes.com/lonza-reported-to-buy-us-biologics-site-from-roche-for-1-2-billion/

Lonza Reported to Buy US biologics site from Roche for $1.2 Billion

The SWISS contract drug manufacturer Lonza claimed this wednesday on March 2oth that they have accepted an agreement and gave a green signal to acquire the Genentech manufacturing facility in Vacaville in California, from Roche for $1.2 billion in cash.

Lonza is predicted to invest around 500 million Swiss francs, which is $754.8 million in order to enhance the facility and improve the capabilities all to accommodate the next generation of the mammalian biologics therapies, which the company has claimed in a stalemate.

At the moment, the Vacaville facility has around 330,000 litres of bioreactor capacity which makes this one of the biggest biologics manufacturing siles globally if measured by volume.

-The Vacaville site is a highly valuable strategic acquisition that will make capacity immediately available for our customers and unlock future growth for our biologics division." is what was claimed by Jean-Christophe Hyvert, who is the president of Biologics al Lonza. Read more- https://luminarytimes.com/lonza-reported-to-buy-us-biologics-site-from-roche-for-1-2-billion/